Rollout of efavirenz-based regimens in option B plus in the prevention of mother-to-child transmission programs: challenges and lessons learned from a postexposure prophylaxis experience

被引：0
作者：
Orikiiriza, Judy T. [1 ,2 ,3 ]
机构：
[1] Trinity Coll Dublin, Dept Immunol, Dublin, Ireland
[2] Makerere Univ, Infect Dis Inst, Coll Hlth Sci, Kampala, Uganda
[3] Rwanda Mil Hosp, Kigali, Rwanda
来源：
AIDS | 2016年 / 30卷 / 15期
关键词：
adherence; adverse effects; efavirenz; prevention of mother-to-child transmission programs; postexposure prophylaxis; THERAPY;
D O I：
10.1097/QAD.0000000000001212
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：N29 / N31
页数：3
相关论文
共 15 条
[1]  
Badal S, ENZYME INHIBITION BI, P365
[2]   A case-control study of HIV seroconversion in health care workers after percutaneous exposure [J].
Cardo, DM ;
Culver, DH ;
Ciesielski, CA ;
Srivastava, PU ;
Marcus, R ;
Abiteboul, D ;
Heptonstall, J ;
Ippolito, G ;
Lot, F ;
McKibben, P ;
Bell, DM .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (21) :1485-1490
[3]   REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT [J].
CONNOR, EM ;
SPERLING, RS ;
GELBER, R ;
KISELEV, P ;
SCOTT, G ;
OSULLIVAN, MJ ;
VANDYKE, R ;
BEY, M ;
SHEARER, W ;
JACOBSON, RL ;
JIMENEZ, E ;
ONEILL, E ;
BAZIN, B ;
DELFRAISSY, JF ;
CULNANE, M ;
COOMBS, R ;
ELKINS, M ;
MOYE, J ;
STRATTON, P ;
BALSLEY, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) :1173-1180
[4]   Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVMET 012 randomised trial [J].
Guay, LA ;
Musoke, P ;
Fleming, T ;
Bagenda, D ;
Allen, M ;
Nakabiito, C ;
Sherman, J ;
Bakaki, P ;
Ducar, C ;
Deseyve, M ;
Emel, L ;
Mirochnick, M ;
Fowler, MG ;
Mofenson, L ;
Miotti, P ;
Dransfield, K ;
Bray, D ;
Mmiro, F ;
Jackson, JB .
LANCET, 1999, 354 (9181) :795-802
[5]  
Joint United Nations Programme on HIV/AIDS (UNAIDS), 2014, 90-90-90: An Ambitious Treatment Target to Help End The AIDS Epidemic
[6]   Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients [J].
Marzolini, C ;
Telenti, A ;
Decosterd, LA ;
Greub, G ;
Biollaz, J ;
Buclin, T .
AIDS, 2001, 15 (01) :71-75
[7]  
MOH, 2014, UG NAT GUID US ANT A
[8]   Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients [J].
Mouly, Stephane ;
Rizzo-Padoin, Nathalie ;
Simoneau, Guy ;
Verstuyft, Celine ;
Aymard, Guy ;
Salvat, Cecile ;
Mahe, Isabelle ;
Bergmann, Jean-Francois .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (02) :200-209
[9]   Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes [J].
Mukonzo, Jackson K. ;
Owen, Joel S. ;
Ogwal-Okeng, Jasper ;
Kuteesa, Ronald B. ;
Nanzigu, Sarah ;
Sewankambo, Nelson ;
Thabane, Lehana ;
Gustafsson, Lars L. ;
Ross, Colin ;
Aklillu, Eleni .
PLOS ONE, 2014, 9 (01)
[10]   HIV/AIDS Patients Display Lower Relative Bioavailability of Efavirenz than Healthy Subjects [J].
Mukonzo, Jackson K. ;
Nanzigu, Sarah ;
Rekic, Dinko ;
Waako, Paul ;
Roshammar, Daniel ;
Ashton, Michael ;
Ogwal-Okeng, Jasper ;
Gustafsson, Lars L. ;
Aklillu, Eleni .
CLINICAL PHARMACOKINETICS, 2011, 50 (08) :531-540
12